KPV Reference Guide: α-MSH C-Terminal Tripeptide and Inflammation Research

KPV is a tripeptide corresponding to the C-terminal three residues (lysine-proline-valine) of α-melanocyte-stimulating hormone (α-MSH). It is one of the most-studied minimal active fragments of a larger peptide hormone — in published research, KPV recapitulates a meaningful portion of α-MSH's anti-inflammatory activity through a mechanism that, in most models, does not appear to require classical melanocortin receptor engagement.

KPV is most commonly studied in mucosal inflammation models — particularly gut and skin — and in mast cell and cytokine research where the goal is to dampen NF-κB-driven inflammatory signaling.

At a glance

Origin: the active C-terminus of α-MSH

α-MSH is a 13-residue peptide hormone that engages MC1R-MC5R receptors and produces a wide range of effects — pigmentation, appetite suppression, and anti-inflammatory tone among them. Cleavage and fragment studies in the 1990s established that much of the anti-inflammatory activity of α-MSH could be reconstituted by its C-terminal tripeptide (residues 11–13), Lys-Pro-Val. KPV was developed as a research tool around that finding.

Crucially, KPV lacks the central pharmacophore of α-MSH that binds the melanocortin receptor orthosteric pocket — and in published in-vitro work it shows little affinity for MC1R-MC5R. The anti-inflammatory activity it retains therefore points to a mechanism separate from classical melanocortin signaling.

Mechanism: receptor-independent anti-inflammation

The current published model of KPV activity centers on cellular uptake (in part through the PEPT1 oligopeptide transporter expressed on intestinal epithelium) followed by intracellular interference with NF-κB activation. Reported downstream effects include reduced production of pro-inflammatory cytokines (TNF-α, IL-6, IL-8), suppressed NF-κB nuclear translocation, and attenuated mast cell degranulation. Because the mechanism does not require a cell-surface melanocortin receptor, KPV is active in tissues with little MC1R-MC5R expression, including intestinal epithelium.

What research models use it

• Mucosal inflammation: DSS and TNBS colitis models, where KPV is delivered orally and acts on intestinal epithelium via PEPT1-mediated uptake.
• Skin inflammation:models of dermal inflammation and topical delivery research, building on α-MSH's established skin anti-inflammatory tone.
• Mast cell biology: degranulation assays, histamine release, and IgE-driven mast cell research.
• Cytokine signaling: NF-κB activation, TNF-α and IL-6 production from cultured immune and epithelial cells.

KPV versus other tripeptide research tools

KPV sits in a small group of three-residue peptides that punch above their size in research models — alongside GHK-Cu (copper tripeptide), AHK-Cu, and others. These compounds share a practical advantage: short sequence makes synthesis cleaner and cellular uptake more straightforward, and the small footprint makes them useful additions to multi-component repair-research formulations.

For background on the most-studied copper-binding tripeptide, see the GHK-Cu Reference Guide.

Lab handling

Lyophilized KPV is stable at −20°C for typical research timeframes. It is highly water-soluble and reconstitutes cleanly in bacteriostatic water without cosolvents. Standard practice applies: gentle swirling rather than shaking, aliquoting before freezing, and limiting freeze-thaw cycles. For oral-delivery research models, fresh solutions are typical because dilute peptide stability in aqueous buffer is shorter than the freezer-stable lyophilized cake.

For step-by-step reconstitution that applies to KPV, see How to Reconstitute BPC-157. For pre-computed dilution math at the 10 mg vial size, see the Peptide Dilution Table.

When to choose KPV in a research design

• Mucosal inflammation arm: models where intestinal epithelial uptake via PEPT1 is part of the hypothesis.
• Receptor-independent comparison: paired with a melanocortin receptor agonist (α-MSH, PT-141) to dissociate receptor-mediated from receptor-independent anti-inflammatory effects.
• Multi-component repair research: as a small anti-inflammatory addition to repair-peptide formulations alongside BPC-157, TB-500, or GHK-Cu.

For Research Use Only. Information presented for laboratory and research applications. Not medical advice and not a substitute for qualified scientific judgment. Kalon Research does not provide identity, purity, or quality control documentation with shipments. Buyer assumes all responsibility.